BioMarin Pharmaceuticals
BMRN
438 hedge funds and large institutions have $15.8B invested in BioMarin Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 150 increasing their positions, 145 reducing their positions, and 44 closing their positions.
77% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 44
34% more call options, than puts
Call options by funds: $208M | Put options by funds: $155M
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
7% more funds holding
Funds holding: 411 → 438 (+27)
1.4% more ownership
Funds ownership: 99.72% → 101.12% (+1.4%)
3% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 145
3% less capital invested
Capital invested by funds: $16.3B → $15.8B (-$449M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$146M |
| 2 |
BlackRock
New York
|
+$81.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$60M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$58.4M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$56.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$178M |
| 2 |
SIG
Senator Investment Group
New York
|
-$65.1M |
| 3 |
O
OrbiMed
New York
|
-$55.9M |
| 4 |
Jennison Associates
New York
|
-$43.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$43.6M |
BMRN Hedge Fund Activity: Q4 2017 in Review
438 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2017, worth a combined $15.8B — down 2.8% from $16.3B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new BMRN positions and 44 closed out — a net gain of 34 holders — while 150 added to existing stakes and 145 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $146M. The largest seller was Fidelity Investments, cutting an estimated $178M.
- 438 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2017, up from 411 in Q3 2017.
- Funds reported $15.8B of BioMarin Pharmaceuticals stock for Q4 2017, down 2.8% quarter-over-quarter.
- 78 funds opened new BioMarin Pharmaceuticals positions in Q4 2017 and 44 closed out, a net change of +34 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2017 was Baker Bros. Advisors, an estimated $146M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $178M sold.
Based on aggregated 13F filings for Q4 2017.